Last updated on January 2020

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics


Brief description of study

The primary objective is to characterize the pharmacokinetics of single doses of ceftobiprole in neonates and infants aged 3 months. The secondary objective is to evaluate safety and tolerability of ceftobiprole in neonates and infants aged 3 months.

Clinical Study Identifier: NCT02527681

Find a site near you

Start Over

Norton Children's Hospital

Louisville, KY United States
5.74miles
  Connect »